文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

皮肤病理与PCR鉴别湿疹与银屑病的诊断一致性

Diagnostic concordance of dermatopathology and PCR in differentiating eczema from psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-03-12

该研究比较了皮肤病理评估与基于NOS2/CCL27的RT-qPCR(手工与全自动PsorX-LabDisk)在鉴别银屑病与湿疹中的诊断性能。73例样本经14位皮肤病理医生评估,病理一致性仅为一般(Fleiss κ=0.31),平均准确率76.9%;分子检测灵敏度92.9%、特异度82.2%-84.4%、准确率86.3%-87.7%,在诊断模糊病例中准确率>86%,优于病理的61.7%。

要点

  • 皮肤病理鉴别银屑病与湿疹的观察者间一致性仅为一般(Fleiss κ=0.31)。
  • NOS2/CCL27 RT-qPCR分子检测灵敏度92.9%,准确率86.3%-87.7%。
  • 在诊断模糊病例中分子检测准确率>86%,明显优于病理的61.7%。

核心结论

  • 手工与全自动PsorX-LabDisk分子检测均可作为皮肤病理的可靠、不依赖检查者的补充,用于鉴别银屑病与湿疹。
  • 分子检测可减少诊断模糊性,增强临床信心,支持更精准及时的治疗决策。

研究设计与样本

  • 研究纳入73例福尔马林固定石蜡包埋的银屑病与湿疹皮肤样本,由14位皮肤病理医生独立评估H&E切片。
  • 验证队列来自独立机构共72例样本,由3位皮肤病理医生在相同条件下评估。
  • 分子分析采用基于NOS2和CCL27表达的手工与全自动RT-qPCR工作流。
  • 以参考诊断为标准计算病理与分子分析的灵敏度、特异度和准确率。

主要发现

  • 皮肤病理评估在研究队列和验证队列中均仅呈一般一致性(Fleiss κ=0.31)。
  • 皮肤病理平均诊断准确率为76.9%,灵敏度70%,特异度81.6%。
  • 手工与PsorX-LabDisk的灵敏度均为92.9%,特异度分别为82.2%和84.4%,准确率分别为87.7%和86.3%。
  • 在诊断模糊病例中,分子检测保持高准确率(>86%),而皮肤病理一致性接近随机且准确率低(61.7%)。

临床怎么用

  • 对于临床和组织学特征重叠、难以鉴别银屑病与湿疹的病例,可考虑采用NOS2/CCL27 RT-qPCR分子检测作为辅助手段。
  • 分子检测结果不依赖检查者,有助于提高诊断信心并指导靶向治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted treatments for non-communicable chronic inflammatory skin diseases like eczema and psoriasis offer significant potential for effective therapy. However, therapeutic success requires an accurate diagnosis, which is challenging due to their overlapping clinical and histological features. OBJECTIVES: We aimed at assessing the diagnostic performance of both a manual (MC) and fully automated (PsorX-LabDisk) quantitative real-time polymerase chain reaction (RT-qPCR) test based on the expression of NOS2 and CCL27 compared with conventional dermatopathological evaluation in differentiating psoriasis from eczema. METHODS: Seventy-three formalin-fixed, paraffin-embedded skin samples of psoriasis and eczema were randomly selected and evaluated histopathologically (H&E-stained sections) by 14 dermatopathologists to assess inter-observer variability, quantified using Cohen's and Fleiss' κ. To confirm that the observed variability was not cohort- or rater-specific, a validation cohort (n = 72) from an independent institution was assessed by three dermatopathologists under identical conditions. For molecular analysis, both manual (MC) and automated NOS2/CCL27-based RT-qPCR (PsorX-LabDisk) workflows were applied. Diagnostic performance (sensitivity, specificity, accuracy) of histopathological and molecular analyses was determined against reference diagnoses. RESULTS: Dermatopathological evaluation demonstrated only fair agreement (Fleiss' κ = 0.31) in both study and validation cohort. The mean diagnostic accuracy of dermatopathology was 76.9%, with a sensitivity of 70% and specificity of 81.6%. In comparison, MC and the PsorX-LabDisk achieved sensitivities of both 92.9%, specificities of 82.2% and 84.4% and accuracies of 87.7% and 86.3%, respectively. In diagnostically ambiguous cases, molecular testing maintained high accuracy (>86%), clearly outperforming dermatopathology, which showed near-random agreement and low accuracy (61.7%). CONCLUSIONS: Both MC and PsorX-LabDisk provide a reliable, examiner-independent complement to dermatopathology for differentiating psoriasis and eczema. By reducing diagnostic ambiguity, it enhances clinical confidence and supports more precise and timely therapeutic decisions in inflammatory skin disease management. UNLABELLED: WHAT IS THE DISEASE?: Psoriasis and eczema are common long‐term inflammatory skin diseases that cause symptoms such as itching, redness and scaling and can strongly affect quality of life. Although they are different conditions, they often look similar on the skin and under the microscope, making diagnosis difficult. An accurate diagnosis is essential because modern targeted treatments work only for specific diseases. LOCATION OF THE STUDY: This study was conducted in Germany and the Czech Republic. AIM OF THE STUDY: The aim of this study was to determine how reliably psoriasis and eczema can be distinguished using standard microscope‐based pathology and whether a molecular test could improve diagnostic accuracy, especially in unclear cases. METHODOLOGY: We analysed skin biopsy samples from 73 patients with psoriasis or eczema in Germany. Fourteen expert dermatopathologists independently evaluated the samples to assess agreement between specialists. To confirm the findings, a second group of 72 samples from the Czech Republic was evaluated by three dermatopathologists. All samples were also analysed using a molecular test that measures the presence of two genes (NOS2 and CCL27) using a manual method and a fully automated test (PsorX‐LabDisk). KEY FINDINGS: Pathologists often disagreed when diagnosing psoriasis versus eczema, particularly in difficult cases. The molecular test was more consistent and accurate than standard pathology and performed especially well when the diagnosis was unclear. CONCLUSIONS AND PRACTICAL IMPLICATIONS: Molecular testing can support doctors when traditional diagnosis is uncertain. It may help patients receive appropriate treatment sooner and avoid unnecessary or ineffective therapies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Schmitt A, Proksch S, Gutzweiler L, et al. Diagnostic concordance of dermatopathology and PCR in differentiating eczema from psoriasis. J Eur Acad Dermatol Venereol. 2026. PMID: 41814865. doi:10.1111/jdv.70388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。